Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Elesclomol's Phase III Fizzle Leaves Synta In Need Of Alternatives

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Suspension of Synta/GlaxoSmithKline's Phase III oncology candidate elesclomol amid signs of higher mortality has left developer Synta with a gaping late-stage pipeline hole and in need of a new business plan

You may also be interested in...

Synta And Roche Agree To Co-Develop Anti-Inflammatory Drugs

Deal for Synta’s CRAC channel inhibitor brings $25 million upfront plus potential for $1 billion in milestones.

Weak Result Stops Pfizer’s Tremelimumab Phase III Trial

Failure casts doubt on Bristol/Medarex’s CTLA-4 inhibitor ipilimumab, analysts say.

R&D In Brief

Cell Therapeutics completes enrollment in pixantrone Phase III trial; Elixir Pharmaceuticals type 2 drug mitiglinide enters final Phase III; Takeda stops development of cholesterol compound TAK-475 (lapaquistat); more R&D news, in brief

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts